Key result
ATF3 research grows ~14% annually, emerging as a therapeutic target for obesity-related metabolic and vascular disease.
Why the study?
Exponentially growing research underscores ATF3's emerging role in metabolic regulation, motivating a synthesis of its multisystem regulatory functions, role in vascular dysfunction, and therapeutic potential.
This review highlights ATF3 as a critical determinant of adipose-vascular crosstalk and a potential therapeutic target for obesity-related metabolic and vascular disorders.
ATF3's multisystem metabolic role should not yet alter clinical practice; leaves open cardiometabolic therapeutic targeting for future trials.
Activating transcription factor 3 (ATF3) functions as a central regulator of metabolic homeostasis across multiple physiological systems. A bibliometric analysis of ATF3 research (1993-2025) demonstrates an exponential growth trend, particularly in metabolic disease research demonstrating a robust 14.15% annual growth rate, underscoring ATF3's emerging importance in metabolic regulation. This review synthesizes current knowledge of ATF3's multisystem regulatory functions, spanning endocrine, cardiovascular, nervous, immune, respiratory, digestive, and urogenital systems, and explores the molecular mechanisms by which ATF3 coordinates cellular stress responses, metabolic adaptation, and tissue-specific homeostasis. Particular emphasis is placed on ATF3's regulation of perivascular adipose tissue (PVAT) and its contribution to obesity-related vascular dysfunction. Atf3 deficiency profoundly alters PVAT structure, adipocyte browning capacity, inflammatory signaling, and insulin sensitivity, establishing ATF3 as a critical determinant of adipose-vascular crosstalk. We further evaluate emerging therapeutic strategies targeting ATF3, including natural compounds ( Salvia miltiorrhiza derivatives, sulfuretin) and synthetic modulators (SW20.1, ST32 series), that show promise in experimental metabolic disorders. Current challenges in therapeutic translation include achieving tissue-specific targeting and optimizing drug delivery systems. This comprehensive analysis positions ATF3 as a master regulator linking stress responses with metabolic homeostasis, highlighting its potential as a therapeutic target for obesity-related metabolic and vascular disorders.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) conducted a review in Metabolic and vascular disorders. ATF3 was evaluated. ATF3 research in metabolic disease demonstrates a 14.15% annual growth rate, highlighting its potential as a therapeutic target for obesity-related metabolic and vascular disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: